Get the Stockscreener App
1.47
4.23%
-0.065
Geron Corp stock is traded at $1.47, with a volume of 11.15M.
It is down -4.23% in the last 24 hours and up +6.52% over the past month.
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.
See More
Previous Close:
$1.535
Open:
$1.53
24h Volume:
11.15M
Relative Volume:
0.90
Market Cap:
$943.04M
Revenue:
$196.12M
Net Income/Loss:
$-69.59M
P/E Ratio:
-14.09
EPS:
-0.1043
Net Cash Flow:
$-126.13M
1W Performance:
-0.68%
1M Performance:
+6.52%
6M Performance:
-10.91%
1Y Performance:
+1.38%
1-Day Range:
$1.44
$1.5301
1-Week Range:
$1.43
$1.65
52-Week Range:
$1.04
$2.01
Geron Corp Stock (GERN) Company Profile
Name
Geron Corp
Sector
Industry
Phone
(650) 473-7700
Address
919 EAST HILLSDALE BOULEVARD, FOSTER CITY, CA
Compare GERN vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GERN
Geron Corp
|
1.47 | 1.01B | 196.12M | -69.59M | -126.13M | -0.1043 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Geron Corp Stock (GERN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-10-25 | Resumed | Goldman | Sell |
| May-08-25 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| Feb-27-25 | Downgrade | B. Riley Securities | Buy → Neutral |
| Feb-26-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-05-24 | Initiated | H.C. Wainwright | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Sep-09-24 | Initiated | Leerink Partners | Outperform |
| Apr-30-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Apr-29-24 | Initiated | TD Cowen | Buy |
| Mar-15-24 | Reiterated | Needham | Buy |
| Sep-12-23 | Upgrade | Goldman | Neutral → Buy |
| Mar-28-23 | Initiated | Goldman | Neutral |
| Oct-28-22 | Initiated | Wedbush | Outperform |
| Jul-28-22 | Resumed | B. Riley Securities | Buy |
| Nov-02-21 | Initiated | Robert W. Baird | Outperform |
| Feb-18-21 | Resumed | B. Riley Securities | Buy |
| Aug-03-20 | Initiated | Stifel | Buy |
| Nov-19-19 | Resumed | B. Riley FBR | Buy |
| Sep-03-19 | Initiated | H.C. Wainwright | Buy |
| Aug-15-19 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-09-19 | Upgrade | Needham | Hold → Buy |
| Jan-31-19 | Upgrade | B. Riley FBR | Neutral → Buy |
| Oct-02-18 | Downgrade | B. Riley FBR | Buy → Neutral |
| Jul-05-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Sep-13-16 | Reiterated | FBR & Co. | Outperform |
| Sep-13-16 | Reiterated | FBR Capital | Outperform |
| Dec-07-15 | Reiterated | Piper Jaffray | Overweight |
| Apr-21-15 | Initiated | Oppenheimer | Outperform |
| Jun-12-14 | Upgrade | MLV & Co | Hold → Buy |
| Mar-12-14 | Downgrade | MLV & Co | Buy → Hold |
| Dec-10-13 | Reiterated | MLV & Co | Buy |
| Dec-10-13 | Upgrade | Needham | Hold → Buy |
| Nov-08-13 | Reiterated | MLV & Co | Buy |
| Oct-16-13 | Initiated | MLV & Co | Buy |
| Aug-30-12 | Initiated | Stifel Nicolaus | Buy |
| Jun-28-12 | Initiated | Needham | Hold |
View All
Geron Corp Stock (GERN) Latest News
Geron (NASDAQ:GERN) Stock Price Down 5.2%Here's Why - MarketBeat
GERN|Geron Corp|Price:1.530|Chg%:-0.040 - tradingkey.com
Geron CorporationCommon Stock (NQ: GERN - FinancialContent
Geron (NASDAQ:GERN) Shares Up 6.4%Here's What Happened - MarketBeat
Geron Corporation $GERN Stake Raised by Renaissance Technologies LLC - MarketBeat
Geron (GERN) Stock Looks Reasonable On Sales But Weak On Returns - Yahoo Finance
Geron (GERN) Back In Focus As Fresh Guidance And Earnings Test Its Undervalued Narrative - Yahoo Finance
Geron (GERN) Is Up 14.7% After Issuing First RYTELO Revenue Guide And Narrowing LossesHas The Bull Case Changed? - Yahoo Finance
Geron Corporation Stock (GERN) Opinions on Recent Price Surge and Trial Updates - quiverquant.com
Janus Henderson Group PLC Raises Position in Geron Corporation $GERN - MarketBeat
Geron Stock Price Forecast. Should You Buy GERN? - StockInvest.us
State Street Corporation (GERN) discloses 5.6% beneficial stake in Geron - Stock Titan
HC Wainwright Issues Pessimistic Forecast for Geron Earnings - MarketBeat
Form 8K Geron Corporation For: 6 August By Investing.com - Investing.com South Africa
Is Geron Corp (GERN) on the Right Path After Q2 Earnings Report? - GuruFocus
Geron reports Q2 2026 RYTELO revenue $57.5M; net loss $16.7M; cash $327M - TradingView
Research Analysts Issue Forecasts for Geron Q4 Earnings - MarketBeat
Geron (NASDAQ:GERN) Posts Earnings Results, Misses Expectations By $0.01 EPS - MarketBeat
Geron Corporation (GERN) stock price, news, quote and history - Yahoo Finance Singapore
GERON CORP 2026: Revenue $57.48M, EPS ($0.02) — 10-Q Summary - TradingView
[10-Q] GERON CORP Quarterly Earnings Report - Stock Titan
Geron earnings missed by $0.01, revenue topped estimates - Investing.com
Geron Corp (GERN) (Q2 2026) Earnings Call Highlights: Strong Rev - GuruFocus
Geron Corp (GERN) (Q2 2026) Earnings Call Highlights: Strong Revenue Growth and Strategic ... - Yahoo Finance
Geron Releases Q2 2026 Financial Results - AlphaStreet
Geron (NASDAQ:GERN) rises as Rytelo sales move guidance midpoint within range - TechStock²
Earnings call transcript: Geron tops revenue forecast in Q2 2026 as losses persist - Investing.com
Geron Corporation Q2 2026 Earnings Call Summary - Yahoo Finance
Investors Purchase Large Volume of Geron Call Options (NASDAQ:GERN) - MarketBeat
Geron (GERN) Projects 2026 Revenue Growth Amid Cash-Flow Challen - GuruFocus
Geron Corp (GERN) Q2 Revenue Beats Estimates, But Valuation Refl - GuruFocus
Geron Q2 Earnings Call Highlights - Yahoo Finance
Geron (GERN) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Geron Corp. (GON.SG) Q2 FY2026 earnings call transcript - Yahoo Finance
Geron: Q2 Earnings Snapshot - marketscreener.com
Geron Corporation Reports Second Quarter 2026 Financial Results and Recent Business Highlights - Yahoo Finance
Geron (NASDAQ:GERN) Shares Down 7.1%Should You Sell? - MarketBeat
Geron Corp (GERN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - tradingkey.com
Geron (GERN) Projected to Post Earnings on Wednesday - MarketBeat
Geron Market Sentiment - Benzinga España
Eversept Partners LP Purchases 1,174,900 Shares of Geron Corporation $GERN - MarketBeat
Geron Corp (GERN) Cash Flow - TradingKey
Geron Corp (GERN) Shareholder Structure: Major Shareholders & Institutional Holdings - tradingkey.com
GERN|Geron Corp|Price:1.480|Chg%:-0.090 - tradingkey.com
Geron Corp (GERN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
TradingKey - TradingKey
GERN|Geron Corp|Price:1.290|Chg%:-0.050 - TradingKey
Geron Corp (GERN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
GERN News | GERON CORP (NASDAQ:GERN) - ChartMill
Geron Corporation (GERN) Stock Price, News, Quote & History - Yahoo! Finance Canada
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Geron Corp Stock (GERN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):